Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL)
──────────
I'll write the podcast script now based on the transcript.

WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWN

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Lowe's second quarter fiscal 2026 results, reported August 19th. Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good disclaimer to lead with, because this quarter has a little bit of everything — solid execution undercut by some messy competitive dynamics. Should be a fun one to unpack.

ALEX: Let's start with the topline. Lowe's did $26 billion in sales for the quarter, up 8.3% year-over-year, but that growth is mostly acquisition-driven — comparable sales, meaning existing stores, only rose 0.2%. GAAP diluted EPS came in at $4.27, and adjusted EPS was $4.40, which included an $0.11 benefit from tariff refunds.

JORDAN: And that $0.11 detail matters more than it sounds like at first. CFO Brandon Sink was clear that even excluding the tariff refund, adjusted EPS beat expectations. So the underlying business performed better than the headline number suggests — that refund wasn't propping up an otherwise weak quarter.

ALEX: Right, and comp sales broke down interestingly by month — May was down 0.4%, June up 1.7%, July down 1.2%. Some of that swing is just calendar noise, the July 4th holiday shifted between June and July and moved about 75 basis points back and forth.

JORDAN: But the more important July story wasn't calendar — it was competitive. Management said competitors used their own tariff refund dollars to slash prices, particularly in seasonal categories like grills, patio furniture, and live goods. Lowe's chose not to chase those promotions.

ALEX: Yeah, CEO Marvin Ellison was pretty blunt about that in the Q&A — he said matching those prices "was not in our financial plan" and wasn't "financially prudent." Basically: we can see who got tariff refunds by looking at whose gross margin cratered.

JORDAN: Which is a pretty sharp comment aimed squarely at competitors. But it also tells you something about Lowe's discipline here — they'd rather protect margin than chase a short-term share number in a category they view as transitory. Whether that's the right call long-term is the real debate for investors.

ALEX: Let's talk about where the strength actually showed up, because it wasn't uniform. Lowe's has been leaning hard into what they call the "Total Home" strategy — basically diversifying beyond the DIY homeowner into professional contractors, online, and installed services.

JORDAN: And that strategy is clearly doing the heavy lifting. Online sales grew nearly 16% — that's back-to-back quarters above 15%. Pro customers kept growing too, especially small and medium-sized contractors. Home Services, the "do it for me" installation business, also grew. Meanwhile, discretionary DIY spending — think big remodeling projects — stayed under pressure.

ALEX: One thing that jumped out to me was Mylow, their AI shopping assistant. They said it's fielded over 25 million questions from customers and store associates combined, and customers who use it convert at three times the rate of those who don't.

JORDAN: That's a genuinely strong stat. It's early days for how much AI tools move the needle in retail, but a 3x conversion lift is not a rounding error — that's a real behavioral signal. Worth watching whether that holds up as adoption scales further.

ALEX: On the Pro side, they've been building out FBM and ADG — Foundation Building Materials and Artisan Design Group, two acquisitions aimed at bigger professional and construction customers

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL)
──────────
# Beta Finch Podcast Script - Lowe's Q1 2027 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we decode corporate earnings calls so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Lowe's first quarter 2027 results, and folks, this one's got some interesting twists.

Before we jump in though, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. So Lowe's just reported their Q1 2027 numbers, and there's actually quite a bit to unpack here. The headline numbers look solid - they hit $23.1 billion in sales, up over 10% year-over-year, with comparable sales growing 0.6%. That might not sound like much, but in this housing environment, any positive comp growth is actually pretty impressive.

**ALEX:** Absolutely. And their adjusted earnings per share came in at $3.03, up nearly 4% from last year. But Jordan, what really caught my attention was how weather played such a big role in shaping their quarter. February storms apparently knocked 30 basis points off their entire quarterly performance just from the first weekend alone!

**JORDAN:** That's wild when you think about it - one weekend of bad weather impacting an entire quarter. But they recovered nicely. March comps were actually up 2.1% as spring weather kicked in. What I found interesting is how CEO Marvin Ellison described this as "the most difficult housing market since the financial crisis," yet they're still managing positive growth.

**ALEX:** Right, and that's where their strategy really shines through. They're not just sitting back waiting for the housing market to recover. Their "Total Home" strategy is firing on multiple cylinders. Let's talk about some of these growth drivers - their online business grew 15.5% in the quarter, which is huge.

**JORDAN:** And here's where it gets really interesting from a tech perspective, Alex. They've got this AI shopping assistant called "Mylow" that's now handling over 1 million customer inquiries per month. But get this - customers who use Mylow have triple the conversion rate of those who don't. That's not just incremental improvement, that's transformational.

**ALEX:** That's a perfect example of AI actually delivering measurable business results rather than just being a buzzword. And they're using AI on the associate side too with something called "Mylow Companion" - their store employees have asked over 5 million questions through this system since launch. Even veteran employees are embracing it because it's making them more effective.

**JORDAN:** Speaking of effectiveness, let's talk about their Pro business, because this is where Lowe's is really differentiating itself. They're seeing continued strength with small to medium professional contractors, and they've launched this "Pro Extended Aisle" concept that lets them offer products without actually stocking them in stores.

**ALEX:** It's like having infinite shelf space, right? And they're backing that up with same-day delivery for loyalty members on orders over $25. But here's something that really stood out to me - they just announced a $250 million investment in skilled trades training through the Lowe's Foundation. That's not just corporate social responsibility, that's strategic.

**JORDAN:** Exactly! They're literally investing in creating their future customers. If there aren't enough skilled tradespeople, that directly impacts demand for their products. It's brilliant long-term thinking. Now, let's talk about the challenges because it wasn't all roses. Gross margins were down 70 basis points, largely due to

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL)
──────────
# Beta Finch Podcast Script: Lowe's Q4 2026 Earnings Breakdown

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into conversations you can actually follow. I'm Alex.

**JORDAN**: And I'm Jordan. Today we're diving into Lowe's fourth quarter 2026 results, and there's quite a bit to unpack here.

**ALEX**: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Absolutely. Now, let's talk Lowe's. Alex, what were the headline numbers that caught your attention?

**ALEX**: Well, Lowe's delivered $20.6 billion in Q4 sales with comparable sales up 1.3%, which is actually pretty solid given the challenging environment they're operating in. For the full year 2025, they hit $86.3 billion in sales with adjusted earnings per share of $12.28 - that's a 2% increase year-over-year.

**JORDAN**: What I found interesting is how they managed to hold their adjusted operating margins flat despite some serious headwinds. CEO Marvin Ellison was pretty candid about the challenging macro environment - consumers are still hesitant about big-ticket DIY projects, and the housing market remains under pressure from high mortgage rates.

**ALEX**: Speaking of headwinds, they made some tough decisions too. Lowe's announced they're eliminating about 600 corporate and support roles as part of what they call their "perpetual productivity improvement" initiatives. But here's what's notable - they're simultaneously giving out $125 million in discretionary bonuses to frontline workers.

**JORDAN**: That's a fascinating contrast, isn't it? Cut corporate overhead while rewarding the people actually serving customers. It shows they're being very strategic about where they're investing versus where they're cutting costs.

**ALEX**: Exactly. And speaking of investments, let's talk about their growth engines. Three areas really stood out: Pro customers, online sales, and home services. Online grew 10.5% in the quarter, and they set new records on Black Friday and Cyber Monday. Their Lowe's app was actually the number one free shopping app on Apple's App Store on Black Friday.

**JORDAN**: The Pro business momentum is really interesting too. They're expanding their Pro sales force and rolling out this AI-enabled "Pro Companion" tool that helps sales associates prepare for customer conversations. It gives them instant access to relevant information so they can walk into meetings with recommendations already prepared.

**ALEX**: And then there are the big acquisitions - Foundation Building Materials, or FBM, and Artisan Design Group, or ADG. Together, these are expected to contribute about $8 billion in sales for 2026. The strategy here is to create what Ellison calls a "total home" solution for builders - basically everything they need for interior spaces.

**JORDAN**: Though it's worth noting these acquisitions are diluting operating margins by about 30 basis points in 2026, or 50 basis points on an annualized basis. But management says they're earnings accretive overall, which is the key metric.

**ALEX**: Let's talk guidance because this is where things get interesting. For 2026, they're forecasting sales between $92 billion and $94 billion, with comparable sales flat to up 2%. That's a wider range than they usually provide.

**JORDAN**: Right, and when an analyst asked about that wider range, Ellison was pretty transparent. He said there are just too many variables - unpredictable tariffs, high interest rates, and uncertain consumer demand. They're essentially saying "we're confident we'll outperform the market, but the market itself is really hard t

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Eli Lilly's Q2 2026 results, and Jordan, I'll just say it up front — this was a big one.

JORDAN: Big is an understatement. But before we get into the numbers, our standard reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, with that said — let's talk numbers. Lilly's revenue grew 48% year-over-year in Q2. Their key products alone added almost $6.8 billion, and get this — oncology, immunology, and neuroscience combined grew 121% versus last year.

JORDAN: That's a company firing on basically every cylinder. And the incretin franchise — Zepbound and Mounjaro — is still the engine room. Combined, those two brought in $14.9 billion in the quarter, contributing $6.3 billion of the total growth.

ALEX: Gross margin ticked up to 86.3%, non-GAAP EPS came in at $8.38 — though that includes a $3.03 hit from acquired R&D charges, so the underlying number is even stronger. And naturally, they raised full-year guidance: revenue now expected between $85 and $87 billion.

JORDAN: Which, by the way, is up $3 billion at the low end and $2 billion at the high end from prior guidance. That's not a small tweak — that's a company that's genuinely outperforming its own expectations.

ALEX: Let's talk geography for a second, because the international story here is wild. China revenue grew 93% in constant currency. Rest of world — think Latin America, Asia — grew 136%. Lilly's international incretin market share is now around 55% globally.

JORDAN: And this is the piece I think investors sometimes underweight — Mounjaro's global rollout is still in relatively early innings in a lot of these markets. Management basically said future growth outside the U.S. is going to come from market penetration, not just new country launches, since most of the big launch wave already happened last year.

ALEX: Which actually ties into one of the more interesting analyst questions on the call — someone pushed back on guidance, basically asking "wait, doesn't this guide imply deceleration versus Q2?" And CFO Lucas Montarce had a pretty candid answer.

JORDAN: Yeah, he pointed to a few real factors — there were some one-time favorable adjustments to rebate and discount estimates this quarter that won't repeat, last year's back half had a huge bolus of new-market Mounjaro launches that's now lapped, and there's normal seasonality — European summer holidays hit Q3, and diabetes has its own seasonal pattern in Q4. So it's less "conservative sandbagging" and more "the comp gets harder."

ALEX: Fair enough. Now let's talk about the newer story here — Foundayo, their oral GLP-1. The U.S. launch has been a bit of a slow burn, but management said they're now seeing real inflection. Prescriber count went from 8,000 last quarter to 36,000 now, and the last week of July nearly doubled monthly volume.

JORDAN: The Medicare GLP-1 Bridge Program is a big deal too — it launched July 1st and gives 20 million eligible Americans coverage for obesity GLP-1s at just $50 a month out-of-pocket. That's a 35% expansion in coverage overnight. Early signs are heavily skewed toward injectables — about 80% — but they're seeing real new-patient uptake on both fronts.

ALEX: And internationally, the UAE numbers turned heads — $31 million in Foundayo sales in a single quarter, which is nearly half of total U.S. sales. One analyst flagged that as a signal of "explosive potential" once Foundayo rolls out more broadly, which management confirmed is coming mostly in 2027.

JORDAN: On the pipeline side, retatrutide is the one to watch. Three positive Phase III trials — TRIUMPH-1, 2,

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script - Eli Lilly Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.

**ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.

**JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.

**ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.

**JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.

**ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.

**JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.

**ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.

**JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist -

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**Beta Finch Podcast Script: Eli Lilly Q4 2025 Earnings**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Eli Lilly's blockbuster Q4 2025 results - and folks, when I say blockbuster, I mean it. This pharmaceutical giant just delivered some truly staggering numbers.

But before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And wow, where do we even start with these numbers? Lilly just reported 45% full-year revenue growth - that's not a typo, folks - forty-five percent. We're talking about $65.2 billion in revenue for 2025, with earnings per share jumping 86% to $24.21.

**ALEX**: It's almost surreal when you see numbers like that from a major pharma company. Jordan, what's driving this incredible performance?

**JORDAN**: It all comes down to one word: incretins. These are the diabetes and obesity drugs that have become absolute juggernauts. Their key products - we're talking Mounjaro, Zepbound, and their international rollouts - generated over $13 billion in Q4 revenue alone and grew 91% compared to the same quarter last year.

**ALEX**: Let's break that down for our listeners. Mounjaro is their diabetes drug, Zepbound is the obesity treatment, but they're essentially the same molecule - tirzepatide - just branded differently for different conditions. And the demand has been absolutely explosive.

**JORDAN**: Exactly. What's fascinating is how they've captured market leadership. In the US, Mounjaro now has over 55% of new prescriptions in the diabetes incretin market, while Zepbound commands nearly 70% share in the branded obesity market. But here's what really caught my attention - they're not just winning in the US anymore.

**ALEX**: Right, their international business has been crushing it. CEO David Ricks mentioned they're now the incretin market share leader outside the US as well. That's a huge development because historically, US pharma companies have struggled to replicate their domestic success internationally, especially in obesity treatments.

**JORDAN**: And they're not slowing down. Looking ahead to 2026, management guided to revenue between $80-83 billion. That's another 25% growth at the midpoint. But here's where it gets interesting - they're expecting significant pricing headwinds.

**ALEX**: This is crucial for investors to understand. Lilly is projecting price declines in the low-to-mid teens for 2026. That's a massive headwind, but they believe volume growth will more than offset it.

**JORDAN**: The pricing pressure comes from several factors. First, they struck a deal with the US government to provide obesity medicines to Medicare patients for just $50 per month out-of-pocket starting no later than July 1st. That's huge for patient access but means lower prices for Lilly.

**ALEX**: They're also facing competition from oral versions of these drugs. During the call, they discussed launching their own oral obesity treatment, orforglipron, which they expect to get FDA approval for in Q2 2026.

**JORDAN**: The oral competition point is really interesting. When Novo Nordisk launched oral Wegovy recently, instead of cannibalizing existing injectable sales, it actually expanded the overall market. Lilly's management seems confident this trend will continue - that oral options bring new patients into treatment rather than just switching existing ones.

**ALEX**: Let's talk about their direct-to-consumer business because this is revolutionary for pharma. They've reached 1 million patients on their US direct-to-patient platform.

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
WELCOME TO BETA FINCH

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Linde's second quarter 2026 results — ticker LIN, the industrial gas giant.

JORDAN: Lots to unpack here, Alex. Records on one side, some real margin headaches on the other.

ALEX: Exactly — but before we get into it, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good to have that out of the way. So let's start with the headline numbers.

ALEX: Linde posted record sales and EPS this quarter — both growing near double digits. Sales came in at $9.3 billion, up 9% year-over-year and 6% sequentially. EPS hit $4.50, up 10% from a year ago.

JORDAN: And the backlog story is honestly the standout. It jumped by $1 billion to a record $8.1 billion, driven by a huge new electronics win in the U.S. — advanced semiconductor fabs, tied right into the AI hardware buildout.

ALEX: CEO Sanjiv Lamba was pretty upbeat about that pipeline. He said he expects the backlog to still finish the year with an "eight handle" — meaning above $8 billion — even after they start up more than 20 projects worth about $1.3 billion in the back half.

JORDAN: That's the growth engine working exactly as designed. But here's the catch — margins didn't cooperate this quarter.

ALEX: Right, operating margins excluding cost pass-through actually declined about 30 basis points year-over-year. And management wasn't shy about saying they're "not satisfied" with that.

JORDAN: The big culprit is their U.S. home care business — Lincare. CFO Matt White said the drag from that business is running about 30% higher than analysts had modeled — so more like $130-plus million of margin headwind this year, not the $100 million some were estimating.

ALEX: That business has been fighting labor cost inflation and reimbursement policy changes. And interestingly, Sanjiv basically confirmed they're evaluating strategic options — could mean partial or full divestiture down the road.

JORDAN: Which is a pretty significant signal. When a CEO says "we're evaluating the strategic fit, in part and as a whole," that's corporate-speak for "this could be sold."

ALEX: Strip Lincare out, though, and the picture flips — Americas margins would've actually been up 20 basis points. So the core gases business is healthy; it's really this one legacy healthcare unit dragging things down.

JORDAN: There's also a smaller mix effect — higher hard goods and equipment sales, especially in packaged gas and electronics equipment in Asia Pacific, which are lower-margin but were framed as a good sign of manufacturing recovery.

ALEX: Let's talk end markets, because there's some genuinely interesting texture here. Electronics was the star — 18% growth year-over-year, driven by AI-related hardware demand and project startups.

JORDAN: And there was a nugget most people probably missed — a Taiwan joint venture is investing roughly $800 million to build and operate air separation units and hydrogen production for new semiconductor and advanced packaging facilities. That's not even in the official backlog number.

ALEX: Manufacturing was the fastest-growing industrial market, with aerospace alone contributing more than a third of that growth. And there's a real U.S. recovery narrative — package gas sales growing mid-to-high single digits, with hard goods up double digits.

JORDAN: Then there was the Strait of Hormuz question, which came up a few times in Q&A. Linde's helium supply has been disrupted by the broader Middle East situation, but Sanjiv said the team has actually used the disruption to sign new long-term helium customers, leveraging diverse supply sources.

ALEX: Pri

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
# Beta Finch Podcast Script - Linde Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and joining me as always is Jordan. Today we're unpacking Linde's Q1 2026 results - the industrial gas giant that just delivered another solid quarter despite some serious global headwinds.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, what a quarter to analyze. Linde really showed why they're considered the gold standard in industrial gases. EPS of $4.33 was up 10% year-over-year, with operating margins hitting that impressive 30% mark. When you've got geopolitical chaos, supply chain disruptions, and economic uncertainty swirling around, delivering those kinds of numbers is no small feat.

**ALEX:** Absolutely. And let's talk about that revenue picture - $8.8 billion in sales, up 8% year-over-year. But here's what I found interesting, Jordan: when you strip out the 5% currency tailwind and 1% from acquisitions, underlying sales growth was a more modest 3%. That tells us the real story is about pricing discipline rather than volume explosions.

**JORDAN:** Exactly right, Alex. CEO Matthew White was pretty clear about this during the call - they're seeing 2% higher pricing and just 1% volume growth. And when you dig into the geographic breakdown, it's really a tale of three regions. The Americas are firing on all cylinders with base volume growth, APAC is holding steady thanks to project startups, but EMEA? That's where the weakness is concentrated.

**ALEX:** The EMEA situation is fascinating from a macro perspective. White mentioned they're seeing production shifting away from Continental Europe to more feedstock-advantaged assets in the Americas. He basically said if your feedstock comes on a ship, you're in trouble right now, but if it's pipeline or rail-based, you're in a better position.

**JORDAN:** And that brings us to one of the most interesting parts of this call - helium. I mean, who would have thought helium would be such a hot topic on an earnings call? But with the Middle East conflict disrupting supply chains, Linde is sitting pretty with their diversified sourcing. They're about 85-90% contracted on helium, and White said they're already securing new long-term agreements rather than chasing spot market gains.

**ALEX:** Smart strategy there. But let's talk about the real growth engine everyone's buzzing about - commercial space. This is where it gets exciting, Jordan. Linde mentioned they're investing over $1 billion in ultra-high-purity plants for advanced semiconductor fabs, and the space business is growing so fast they might break it out as a separate segment when it hits 5% of sales.

**JORDAN:** The math on that is pretty striking, Alex. Five percent of sales would be about $1.7 billion annually. White mentioned they previously thought space might hit $1 billion by decade's end, but now they're talking about potentially reaching $1.7 billion. That's not just growth - that's explosive growth in a completely new market.

**ALEX:** And the drivers make sense. It's all about launch frequency, rocket size, and propellant type. Linde supplies oxygen for oxidizer and nitrogen for densification, plus hydrogen for hydrogen-fueled rockets. With companies racing to build satellite constellations and the entire commercial space economy taking off, Linde is positioned right in the sweet spot.

**JORDAN:** Now let's address the elephant in the room - guidance. For Q2, they're guiding $4.40 to $4.50 EPS, which is 8-10% growth. Full year guidance is $17.60 to $17.90, representing 7-9% growth. Here's what I fin

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
# Beta Finch Podcast Script: Linde Q4 2025 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is Jordan. Today we're diving into Linde's Q4 2025 results, and folks, this industrial gas giant just delivered some impressive numbers despite a pretty challenging macro environment.

Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And what a quarter it was for Linde! They posted record quarterly and annual performance across operating profit, margins, and EPS. Fourth quarter sales hit $8.8 billion, up 6% year-over-year, with EPS of $4.20 - also up 6%. But here's what's really impressive - they maintained a 29.5% operating margin despite all the industrial headwinds.

**ALEX**: That margin performance is remarkable, especially when you consider what CEO Sanjiv Lamba called "a study in contrast" in the economic environment. On one hand, you had this massive AI and digital infrastructure boom driving unprecedented activity. But on the other hand, traditional industrial markets like manufacturing, metals, and chemicals were still struggling.

**JORDAN**: Exactly. And Lamba really painted this picture of geographic unevenness. The US remained resilient - no surprise there - with growth across almost every end market. Electronics and commercial space really stood out. But Europe? Still broadly weak across manufacturing sectors, though there were some bright spots in Scandinavian countries and maybe - and I stress maybe - some early optimism in Germany.

**ALEX**: What caught my attention was their commentary on China. After several tough quarters, Lamba mentioned they're finally seeing some bottoming out. Their China merchant business actually grew faster than the published industrial production number for the first time in a while. That's significant.

**JORDAN**: Absolutely. And let's talk about what's really driving growth here - their project backlog. They're sitting on a record $10 billion backlog, and that doesn't even include over half a billion in space-related investments. This space opportunity is fascinating, Alex. They're supporting about 65-75% of all launches, and with 189 launches last year, that's serious business.

**ALEX**: The space angle is really compelling. They just started up a plant in Brownsville in January, and Lamba mentioned they're building out networks in Texas and Florida - the two major launch hubs. He's expecting this to become a billion-dollar business for them in the coming years. Double-digit growth in a secular trend - that's exactly what investors want to see.

**JORDAN**: And speaking of growth investments, their CapEx jumped 17% in Q4, largely driven by that record project backlog. Now, this did pressure their return on capital down to the low-to-mid 20% range, but management says that's expected and temporary as these projects come online.

**ALEX**: Let's talk guidance because this is where it gets interesting. They're projecting 2026 EPS growth of 6-9%, which puts them in the $17.40 to $17.90 range. Now, some analysts were hoping for that 10%+ growth we've seen historically, so this might seem a bit conservative.

**JORDAN**: It definitely feels conservative, and management admitted as much. CFO Matt White used words like "guarded" and "prudent." But here's the thing - they're assuming zero base volume growth and are essentially letting investors plug in their own macro assumptions. That's smart positioning in an uncertain environment.

**ALEX**: What I found most intriguing in the Q&A was the discussion around restructuring. They took $230 million in restructuring charges in Q4, mostly in EMEA, and expe

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Coca-Cola's second quarter 2026 results, and honestly, Jordan, this is a fun one — FIFA World Cup, Marriott winning back after 34 years, a lot going on.

JORDAN: Yeah, it's a loaded quarter. Before we jump in, quick disclaimer.

ALEX: Right — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Perfect, let's get into it. So headline numbers: organic revenue grew 6%, unit case volume grew 5%. That's a strong beat, but there's a catch.

ALEX: Right, they were cycling an easier comp from last year, plus favorable weather and that huge FIFA World Cup activation. On a two-year average basis, volume growth was actually 2%, which management says is more reflective of the underlying trend.

JORDAN: And that 2% is basically in line with where Coke's been running for years — CFO John Murphy pointed out the industry has grown 3-4% historically, and Coke's long-term algorithm target is 4-6%, with the ambition to be at the high end.

ALEX: Let's talk profitability, because this was arguably the bigger story. Comparable gross margin was up about 120 basis points, operating margin up about 90 basis points. EPS came in at $0.97, up 11%, though two points of that was currency tailwind.

JORDAN: One analyst even called it a potential all-time-record operating margin quarter for Coke. And free cash flow was strong too — about $6.9 billion, up year over year. Balance sheet's in great shape, net debt leverage at 1.4 times EBITDA, well below their 2-2.5x target range.

ALEX: And they raised guidance. Organic revenue growth now expected around 5%, at the high end of prior guidance. Comparable currency-neutral EPS growth bumped up to 7-8%, and all-in comparable EPS growth now guided at 9-10% versus the $3 EPS base in 2025.

JORDAN: Worth noting there's some noise in there — divestitures, mainly the pending sale of Coca-Cola Beverages Africa, are expected to be a 2-3% headwind to revenue and about 1% headwind to EPS. Currency is actually helping this year, flipping from a longtime headwind to roughly a one-point tailwind on revenue and three points on EPS.

ALEX: Now let's talk strategy, because the FIFA World Cup campaign was clearly a centerpiece. CEO Henrique Braun said trademark Coca-Cola grew volume 5% for the quarter — the strongest in 17 years excluding COVID recovery.

JORDAN: And the numbers behind the activation are wild — over 1 billion Panini stickers distributed across 40+ markets, 25 million first-party data points collected, more than 9 billion views generated through digital and social activations. Average incidence at World Cup venues topped 80%, a record.

ALEX: The interesting question from an analyst was basically: was this a one-time sugar high, or does it stick? Management's answer was that the real value is the first-party data and consumer insights carrying forward into future campaigns — things like "Coke and Meals" moments in the second half.

JORDAN: Regionally, North America had a strong quarter — gained value and volume share, grew revenue and profit. Relaunched Mr. Pibb grew volume over 20%, which is a nice example of their innovation engine working. Latin America gained share too, though Mexico remains tough while Brazil's improving.

ALEX: EMEA gained share but profit actually declined due to investment phasing. And Asia Pacific — this got some analyst pushback — operating income declined there as Coke invests heavily in affordability and revenue growth management in India and China to expand the consumer base.

JORDAN: Management framed that as deliberate — playing the l

This episode includes AI-generated content.